Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-0084 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GDC-0084 | DRUG | Multiple doses |
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Interval of at least 12 weeks from completion of adjuvant radiotherapy for gliomas to study entry * Karnofsky Performance Status of \>/= 70 at screening * Confirmed measurable disease per RANO * Adequate hematologic and organ function Pa...
GDC-0084 is an investigational small molecule being studied for the treatment of glioblastoma and glioma, which are types of high-grade brain tumors. It is intended for patients with progressive or recurrent high-grade glioma. The drug is currently in clinical development and has not been approved by regulatory authorities.
GDC-0084 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded over-the-counter under the ticker symbol RHHBY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug in patients with brain tumors.
GDC-0084 is in Phase 1 clinical development. This early-stage trial is designed to assess the drug's safety, tolerability, and pharmacokinetics in patients with progressive or recurrent high-grade glioma. The drug is investigational and has not received FDA approval for any indication.
GDC-0084 has been studied in one completed clinical trial with the identifier NCT01547546. This Phase 1 study enrolled 29 participants with glioblastoma or glioma and was conducted in the United States and Spain. The trial was uncontrolled, meaning there was no comparison group, and it included patients aged 18 years and older.
GDC-0084 is the primary name for this investigational compound. No alternative names have been reported for this drug in the available clinical trial information. It is a distinct small molecule being developed by Roche for the treatment of high-grade gliomas.